BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Etcamah (Camizestrant) readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of Etcamah (Camizestrant)\, from ClinicalTri
 als.gov estimates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT05774951-2423@assetmemo.bio
DTSTAMP:20261121T005602Z
DTSTART;VALUE=DATE:20270420
DTEND;VALUE=DATE:20270421
SUMMARY:Etcamah (Camizestrant): Phase 3 readout est. (NCT05774951)
DESCRIPTION:Etcamah (Camizestrant)\, phase 3\, Breast Cancer.\nStudy: A Stu
 dy of Camizestrant in ER+/HER2- Early Breast Cancer After at Least 2 Years
  of Standard Adjuvant Endocrine Therapy\nEstimated primary completion: 20 
 April 2027. This is a ClinicalTrials.gov estimate\, not a confirmed readou
 t date\, and it can move.\nDrug page: https://assetmemo.bio/drug/camizestr
 ant#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT
 05774951
URL:https://assetmemo.bio/drug/camizestrant#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04644068-2423@assetmemo.bio
DTSTAMP:20261121T005602Z
DTSTART;VALUE=DATE:20270528
DTEND;VALUE=DATE:20270529
SUMMARY:Etcamah (Camizestrant): Phase 1/2 readout est. (NCT04644068)
DESCRIPTION:Etcamah (Camizestrant)\, phase 1/2\, HR+/HER2- Metastatic Breas
 t Cancer.\nStudy: Study of AZD5305 as Monotherapy and in Combination With 
 Anti-cancer Agents in Patients With Advanced Solid Malignancies\nEstimated
  primary completion: 28 May 2027. This is a ClinicalTrials.gov estimate\, 
 not a confirmed readout date\, and it can move.\nDrug page: https://assetm
 emo.bio/drug/camizestrant#upcoming-events\nRegistry record: https://clinic
 altrials.gov/study/NCT04644068
URL:https://assetmemo.bio/drug/camizestrant#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06188520-2423@assetmemo.bio
DTSTAMP:20261121T005602Z
DTSTART;VALUE=DATE:20270630
DTEND;VALUE=DATE:20270701
SUMMARY:Etcamah (Camizestrant): Phase 1/2 readout est. (NCT06188520)
DESCRIPTION:Etcamah (Camizestrant)\, phase 1/2\, HR+/HER2- Metastatic Breas
 t Cancer.\nStudy: A First-in-human Dose Escalation and Expansion Study to 
 Evaluate the Safety\, and Tolerability of AZD8421 Alone or in Combination 
 in Participants With Selected Advanced or Metastatic Solid Tumors\nEstimat
 ed primary completion: 30 June 2027. This is a ClinicalTrials.gov estimate
 \, not a confirmed readout date\, and it can move.\nDrug page: https://ass
 etmemo.bio/drug/camizestrant#upcoming-events\nRegistry record: https://cli
 nicaltrials.gov/study/NCT06188520
URL:https://assetmemo.bio/drug/camizestrant#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07427394-2423@assetmemo.bio
DTSTAMP:20261121T005602Z
DTSTART;VALUE=DATE:20271228
DTEND;VALUE=DATE:20271229
SUMMARY:Etcamah (Camizestrant): Phase 2 readout est. (NCT07427394)
DESCRIPTION:Etcamah (Camizestrant)\, phase 2\, HR+/HER2- Metastatic Breast 
 Cancer.\nStudy: Study to Evaluate the Safety and Tolerability of Camizestr
 ant in Combination With Atirmociclib in Women With Advanced Breast Cancer\
 nEstimated primary completion: 28 December 2027. This is a ClinicalTrials.
 gov estimate\, not a confirmed readout date\, and it can move.\nDrug page:
  https://assetmemo.bio/drug/camizestrant#upcoming-events\nRegistry record:
  https://clinicaltrials.gov/study/NCT07427394
URL:https://assetmemo.bio/drug/camizestrant#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07195227-2423@assetmemo.bio
DTSTAMP:20261121T005602Z
DTSTART;VALUE=DATE:20280229
DTEND;VALUE=DATE:20280301
SUMMARY:Etcamah (Camizestrant): Phase 2 readout est. (NCT07195227)
DESCRIPTION:Etcamah (Camizestrant)\, phase 2\, HR+/HER2- Metastatic Breast 
 Cancer.\nStudy: Efficacy and Safety of Camizestrant Plus Ribociclib in Pat
 ients With Breast Cancer\nEstimated primary completion: February 2028. Thi
 s is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it
  can move.\nDrug page: https://assetmemo.bio/drug/camizestrant#upcoming-ev
 ents\nRegistry record: https://clinicaltrials.gov/study/NCT07195227
URL:https://assetmemo.bio/drug/camizestrant#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07840443-2423@assetmemo.bio
DTSTAMP:20261121T005602Z
DTSTART;VALUE=DATE:20281026
DTEND;VALUE=DATE:20281027
SUMMARY:Etcamah (Camizestrant): Phase 2 readout est. (NCT07840443)
DESCRIPTION:Etcamah (Camizestrant)\, phase 2\, HR+/HER2- Metastatic Breast 
 Cancer.\nStudy: Phase II Study of CAmizestrant in Resectable Endometrial A
 denocarcinoma\nEstimated primary completion: 26 October 2028. This is a Cl
 inicalTrials.gov estimate\, not a confirmed readout date\, and it can move
 .\nDrug page: https://assetmemo.bio/drug/camizestrant#upcoming-events\nReg
 istry record: https://clinicaltrials.gov/study/NCT07840443
URL:https://assetmemo.bio/drug/camizestrant#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07647328-2423@assetmemo.bio
DTSTAMP:20261121T005602Z
DTSTART;VALUE=DATE:20290228
DTEND;VALUE=DATE:20290301
SUMMARY:Etcamah (Camizestrant): Phase 3 readout est. (NCT07647328)
DESCRIPTION:Etcamah (Camizestrant)\, phase 3\, HR+/HER2- Metastatic Breast 
 Cancer.\nStudy: A Phase IIIb Study to Evaluate Camizestrant Plus Ribocicli
 b in ER-positive\, HER2-negative Advanced Breast Cancer\nEstimated primary
  completion: 28 February 2029. This is a ClinicalTrials.gov estimate\, not
  a confirmed readout date\, and it can move.\nDrug page: https://assetmemo
 .bio/drug/camizestrant#upcoming-events\nRegistry record: https://clinicalt
 rials.gov/study/NCT07647328
URL:https://assetmemo.bio/drug/camizestrant#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06380751-2423@assetmemo.bio
DTSTAMP:20261121T005602Z
DTSTART;VALUE=DATE:20291218
DTEND;VALUE=DATE:20291219
SUMMARY:Etcamah (Camizestrant): Phase 3 readout est. (NCT06380751)
DESCRIPTION:Etcamah (Camizestrant)\, phase 3\, HR+/HER2- Metastatic Breast 
 Cancer.\nStudy: Saruparib (AZD5305) Plus Camizestrant or Plus Endocrine Th
 erapy\, Compared With CDK4/6 Inhibitor Plus Endocrine Therapy or Plus Cami
 zestrant in HR-Positive\, HER2-Negative (IHC 0\, 1+\, 2+/ ISH Non-amplifie
 d)\, BRCA1\, BRCA2\, or PALB2m Advanced Breast Cancer\nEstimated primary c
 ompletion: 18 December 2029. This is a ClinicalTrials.gov estimate\, not a
  confirmed readout date\, and it can move.\nDrug page: https://assetmemo.b
 io/drug/camizestrant#upcoming-events\nRegistry record: https://clinicaltri
 als.gov/study/NCT06380751
URL:https://assetmemo.bio/drug/camizestrant#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05952557-2423@assetmemo.bio
DTSTAMP:20261121T005602Z
DTSTART;VALUE=DATE:20300304
DTEND;VALUE=DATE:20300305
SUMMARY:Etcamah (Camizestrant): Phase 3 readout est. (NCT05952557)
DESCRIPTION:Etcamah (Camizestrant)\, phase 3\, Breast Cancer.\nStudy: An Ad
 juvant Endocrine-based Therapy Study of Camizestrant (AZD9833) in ER+/HER2
 - Early Breast Cancer (CAMBRIA-2)\nEstimated primary completion: 4 March 2
 030. This is a ClinicalTrials.gov estimate\, not a confirmed readout date\
 , and it can move.\nDrug page: https://assetmemo.bio/drug/camizestrant#upc
 oming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0595255
 7
URL:https://assetmemo.bio/drug/camizestrant#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
